| Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition AN Hata, MJ Niederst, HL Archibald, M Gomez-Caraballo, FM Siddiqui, ... Nature medicine 22 (3), 262-269, 2016 | 933 | 2016 |
| Prospects for combining targeted and conventional cancer therapy with immunotherapy P Gotwals, S Cameron, D Cipolletta, V Cremasco, A Crystal, B Hewes, ... Nature Reviews Cancer 17 (5), 286-301, 2017 | 917 | 2017 |
| The ALK inhibitor ceritinib overcomes crizotinib resistance in non–small cell lung cancer L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ... Cancer discovery 4 (6), 662-673, 2014 | 914 | 2014 |
| Patient-derived models of acquired resistance can identify effective drug combinations for cancer AS Crystal, AT Shaw, LV Sequist, L Friboulet, MJ Niederst, EL Lockerman, ... Science 346 (6216), 1480-1486, 2014 | 787 | 2014 |
| A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas JR Infante, PA Cassier, JF Gerecitano, PO Witteveen, R Chugh, V Ribrag, ... Clinical Cancer Research 22 (23), 5696-5705, 2016 | 305 | 2016 |
| A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114 AS Crystal, BI Giasson, A Crowe, MP Kung, ZP Zhuang, JQ Trojanowski, ... Journal of neurochemistry 86 (6), 1359-1368, 2003 | 145 | 2003 |
| Membrane topology of γ-secretase component PEN-2 AS Crystal, VA Morais, TC Pierson, DS Pijak, D Carlin, VMY Lee, ... Journal of Biological Chemistry 278 (22), 20117-20123, 2003 | 144 | 2003 |
| Membrane topology and nicastrin-enhanced endoproteolysis of APH-1, a component of the γ-secretase complex RR Fortna, AS Crystal, VA Morais, DS Pijak, VMY Lee, RW Doms Journal of Biological Chemistry 279 (5), 3685-3693, 2004 | 107 | 2004 |
| The transmembrane domain region of nicastrin mediates direct interactions with APH-1 and the γ-secretase complex VA Morais, AS Crystal, DS Pijak, D Carlin, J Costa, VMY Lee, RW Doms Journal of Biological Chemistry 278 (44), 43284-43291, 2003 | 97 | 2003 |
| Candidate genes showing no evidence for association or linkage with Alzheimer's disease using family-based methodologies L Bertram, D Blacker, A Crystal, K Mullin, D Keeney, J Jones, S Basu, ... Experimental gerontology 35 (9-10), 1353-1361, 2000 | 67 | 2000 |
| New targets in advanced NSCLC: EML4-ALK AS Crystal, AT Shaw Clin Adv Hematol Oncol 9 (3), 207-214, 2011 | 58 | 2011 |
| Presenilin modulates Pen-2 levels posttranslationally by protecting it from proteasomal degradation AS Crystal, VA Morais, RR Fortna, D Carlin, TC Pierson, CA Wilson, ... Biochemistry 43 (12), 3555-3563, 2004 | 57 | 2004 |
| No evidence for genetic association or linkage of the cathepsin D (CTSD) exon 2 polymorphism and Alzheimer disease L Bertram, S Guénette, J Jones, D Keeney, K Mullin, A Crystal, S Basu, ... Annals of Neurology: Official Journal of the American Neurological …, 2001 | 41 | 2001 |
| N-glycosylation of human nicastrin is required for interaction with the lectins from the secretory pathway calnexin and ERGIC-53 VA Morais, C Brito, DS Pijak, AS Crystal, RR Fortna, T Li, PC Wong, ... Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease 1762 (9), 802-810, 2006 | 38 | 2006 |
| The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov. 2014; 4: 662–673. doi: 10.1158/2159-8290 L Friboulet, N Li, R Katayama, CC Lee, JF Gainor, AS Crystal, ... CD-13-0846.[Europe PMC free article][Abstract][CrossRef][Google Scholar], 0 | 36 | |
| A phase I study of LSZ102, an oral selective estrogen receptor degrader, with or without ribociclib or alpelisib, in patients with estrogen receptor–positive breast cancer K Jhaveri, D Juric, YS Yap, S Cresta, RM Layman, FP Duhoux, C Terret, ... Clinical Cancer Research 27 (21), 5760-5770, 2021 | 29 | 2021 |
| Evidence against association of the FE65 gene (APBB1) intron 13 polymorphism in Alzheimer's patients SY Guénette, L Bertram, A Crystal, B Bakondi, BT Hyman, GW Rebeck, ... Neuroscience letters 296 (1), 17-20, 2000 | 26 | 2000 |
| Abstract ND09: The discovery and characterization of CFT8634: A potent and selective degrader of BRD9 for the treatment of SMARCB1-perturbed cancers KL Jackson, RV Agafonov, MW Carlson, P Chaturvedi, D Cocozziello, ... Cancer Research 82 (12_Supplement), ND09-ND09, 2022 | 23 | 2022 |
| Variants on a Theme: A Biomarker of Crizotinib Response in ALK-Positive Non–Small Cell Lung Cancer? AS Crystal, AT Shaw Clinical Cancer Research 18 (17), 4479-4481, 2012 | 15 | 2012 |
| Abstract P5-21-04: Phase I/Ib study of the SERD LSZ102 alone or in combination with ribociclib in ER+ breast cancer D Juric, G Curigliano, S Cresta, YS Yap, C Terret, FP Duhoux, ... Cancer research 78 (4_Supplement), P5-21-04-P5-21-04, 2018 | 14 | 2018 |
